The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds
Open accessAbstract
Glucocorticoids remain the frontline treatment for inflammatory disorders, yet represent a double-edged sword with beneficial therapeutic actions alongside adverse effects, mainly in metabolic regulation. Considerable efforts were made to improve this balance by attempting to amplify therapeutic beneficial anti-inflammatory actions and to minimize adverse metabolic actions. Most attention has focused on the development of novel compounds favoring the transrepressing actions of the glucocorticoid receptor, assumed to be important for anti-inflammatory actions, over the transactivating actions, assumed to underpin the undesirable actions. These compounds are classified as selective glucocorticoid receptor agonists (SEGRAs) or selective glucocorticoid receptor modulators (SEGRMs). The latter class is able to modulate the activity of a GR agonist and/or may not classically bind the glucocorticoid receptor ligand-binding pocket. SEGRAs and SEGRMs are collectively denominated SEGRAMs (selective glucocorticoid receptor agonists and modulators). Although this transrepression vs transactivation concept proved to be too simplistic, the developed SEGRAMs were helpful in elucidating various molecular actions of the glucocorticoid receptor, but have also raised many novel questions. We discuss lessons learned from recent mechanistic studies of selective glucocorticoid receptor modulators. This is approached by analyzing recent experimental insights in comparison with knowledge obtained using mutant GR research, thus clarifying the current view on the SEGRAM field. These insights also contribute to our understanding of the processes controlling glucocorticoid-mediated side effects as well as glucocorticoid resistance. Our perspective on non-steroidal SEGRAs and SEGRMs considers remaining opportunities to address research gaps in order to harness the potential for more safe and effective glucocorticoid receptor therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 3×
“These GRs are members of the steroid hormone receptor family of proteins (Rhen & Cidlowski, 2005; Kino et al., 2011).”
BackgroundMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068 · cited 6×
“However, it was later shown that the GR dimerizes not only via this DBD, but also via an LBD interface (Bledsoe et al., 2002).”
MethodInfluentialBledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
DNA binding site sequence directs glucocorticoid receptor structure and activity
Meijsing, S. H., Pufall, M. A., So, A. Y., Bates, D. L., Chen, L., & Yamamoto, K. R. (2009) · Science · doi:10.1126/science.1164265 · Cited by 673 · cited 2×
“…in solution and its capability to transrepress or transactivate specific gene promoters, but that GR’s ability to induce gene expression is co-dictated by the GR-binding sequence and its context and cofactors (Meijsing et al., 2009; Jewell et al., 2012; Watson et al., 2013; Presman et al., 2014).”
BackgroundGenomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594 · cited 2×
“These mechanisms typically inhibit the transcription of pro-inflammatory proteins (e.g. cytokines, enzymes and adhesion molecules) (Stahn & Buttgereit, 2008; Beck et al., 2009).”
BackgroundSteroid-hormone rapid actions, membrane receptors and a conformational ensemble model
Norman, A. W., Mizwicki, M. T., & Norman, D. P. G. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1283 · Cited by 569
Surjit, M., Ganti, K. P., Mukherji, A., Ye, T., Hua, G., Metzger, D., Li, M., & Chambon, P. (2011) · Cell · doi:10.1016/j.cell.2011.03.027 · Cited by 551 · cited 1×
“Interestingly, an attenuating effect of the GRdimmutation was also retrieved for some genes that were downregulated by classic GCs (Surjit et al., 2011).”
BackgroundSchäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Abraham, S. M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., Saklatvala, J., & Clark, A. R. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060336 · Cited by 430 · cited 1×
“Of note, also the dexamethasone-stimulated GRdim mutant is capable of inducing the expression of DUSP1 in COS-7 cells and murine bone marrow macrophages (Abraham et al., 2006; Tchen et al., 2010), albeit not in prednisolone-treated GRdim murine livers (Frijters et al., 2010) .”
BackgroundOakley, R. H., & Cidlowski, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.179325 · Cited by 373 · cited 10×
“Glucocorticoids cannot bind GR-A and GR-P isoforms as a result of their truncated LBD (Oakley & Cidlowski, 2011).”
BackgroundInfluentialGlucocorticoid sensitivity in health and disease
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van Rossum, E. F. C., & Feelders, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.183 · Cited by 310
Beck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., & De Bosscher, K. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0013 · Cited by 298
Self-citationGlucocorticoid Receptor Phosphorylation Differentially Affects Target Gene Expression
Chen, W., Dang, T., Blind, R. D., Wang, Z., Cavasotto, C. N., Hittelman, A. B., Rogatsky, I., Logan, S. K., & Garabedian, M. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0219 · Cited by 280 · cited 1×
“It is proposed that phosphorylation of the S211 residue is a hallmark in the transactivation potential of GR (Blind & Garabedian, 2008; Chen et al., 2008).”
BackgroundWebster, J. C., Jewell, C. M., Bodwell, J. E., Munck, A., Sar, M., & Cidlowski, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.14.9287 · Cited by 261
Tuckermann, J. P., Kleiman, A., Moriggl, R., Spanbroek, R., Neumann, A., Illing, A., Clausen, B. E., Stride, B., Förster, I., Habenicht, A. J. R., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28034 · Cited by 252 · cited 2×
“contact allergy (Tuckermann et al., 2007) and systemic TNF-induced lethal shock (Vandevyver et al.”
BackgroundThe Physiology of Human Glucocorticoid Receptor β (hGRβ) and Glucocorticoid Resistance
LEWIS‐TUFFIN, L. J., & CIDLOWSKI, J. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.001 · Cited by 242
Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor
Clark, A. R., & Belvisi, M. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.004 · Cited by 209 · cited 3×
“Namely, many or all unwanted effects of synthetic GCs can be seen as versions of normal physiological effects of the endogenous cortisol, inappropriately intensified, prolonged or at the wrong point in time of the circadian cycle initiated and continued (Clark & Belvisi, 2012).”
BackgroundCharmandari, E., Kino, T., Ichijo, T., & Chrousos, G. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0040 · Cited by 201
Circadian endocrine rhythms: the hypothalamic–pituitary–adrenal axis and its actions
Nicolaides, N. C., Charmandari, E., Chrousos, G. P., & Kino, T. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12464 · Cited by 183 · cited 1×
“Approximately 10% of the secreted cortisol is free and thereby active; the other 90% is bound to systemic corticosteroidbinding globulins (Chapman et al., 2013; Nicolaides et al., 2014).”
BackgroundDeroo, B. J., Rentsch, C., Sampath, S., Young, J., DeFranco, D. B., & Archer, T. K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4113-4123.2002 · Cited by 164
Zheng, B., Ohkawa, S., Li, H., Roberts‐Wilson, T. K., & Price, S. R. (2010) · The FASEB Journal · doi:10.1096/fj.09-151480 · Cited by 145 · cited 2×
“via the inhibition of PI3K/AKT signaling (Zheng et al., 2010).”
BackgroundCharmandari, E., Chrousos, G. P., Lambrou, G. I., Pavlaki, A., Koide, H., Ng, S. S. M., & Kino, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025612 · Cited by 139
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139
Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator
Zalachoras, I., Houtman, R., Atucha, E., Devos, R., Tijssen, A. M. I., Hu, P., Lockey, P. M., Datson, N. A., Belanoff, J. K., Lucassen, P. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219411110 · Cited by 121 · cited 1×
“Indicative, a recent report on C108297, a partial GR agonist and antagonist, indicates the possibility to selectively target and allow GR signaling in the brain (Zalachoras et al., 2013).”
BackgroundRonacher, K., Hadley, K., Avenant, C., Stubsrud, E., Simons, S. S., Louw, A., & Hapgood, J. P. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.008 · Cited by 121 · cited 6×
“Please cite this article as: Sundahl, N., et al., Selective glucocorticoid recep cology & Therapeutics (2015), http://dx.doi.org/10.1016/j.pharmthera.201 This hypothesis is confirmed for CpdA-bound GR (Ronacher et al., 2009).”
BackgroundMethodInfluentialSchäcke, H., Zollner, T., Döcke, W., Rehwinkel, H., Jaroch, S., Skuballa, W., Neuhaus, R., May, E., Zügel, U., & Asadullah, K. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00238.x · Cited by 121
Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes
Blind, R. D., & Garabedian, M. J. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.01.002 · Cited by 120 · cited 1×
“It is proposed that phosphorylation of the S211 residue is a hallmark in the transactivation potential of GR (Blind & Garabedian, 2008; Chen et al., 2008).”
BackgroundMinireview: Dynamic Structures of Nuclear Hormone Receptors: New Promises and Challenges
Simons, S. S., Edwards, D. P., & Kumar, R. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1334 · Cited by 88 · cited 1×
“An alternative explanation may reside in different ligand-dependent GR-associated cofactor equilibria, which were shown before to be able to modulate the properties of agonist and antagonist complexes of GR (Wang et al., 2004; Simons et al., 2014).”
BackgroundWu, I., Shin, S. C., Cao, Y., Bender, I. K., Jafari, N., Feng, G., Lin, S., Cidlowski, J. A., Schleimer, R. P., & Lu, N. Z. (2013) · Cell Death & Disease · doi:10.1038/cddis.2012.193 · Cited by 64 · cited 4×
“…the proportion of different GR isoforms in a cell modulates the final effects of a presented GC or SEGRM (Gronemeyer et al., 2004; Rhen & Cidlowski, 2005; De Bosscher et al., 2010a; Kino et al., 2011; Wu et al., 2013). tor modulation: New directions with non-steroidal scaffolds, Pharma5.”
BackgroundInfluentialAvenant, C., Ronacher, K., Stubsrud, E., Louw, A., & Hapgood, J. P. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.06.007 · Cited by 49 · cited 8×
“…timing-related cell typedependent, homologous downregulation of the GR via proteosomal degradation subsequent to GR K419 ubiquitination (Deroo et al., 2002), the SEGRMCpdAdoes not at all induceGR degradation in various cell types (Avenant et al., 2010; Gossye et al., 2010; Drebert et al., 2015).”
BackgroundInfluential
Cited by
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Mechanisms of NF-κB p65 and strategies for therapeutic manipulation
Giridharan, S., & Srinivasan, M. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s140188 · Cited by 686
A General Introduction to Glucocorticoid Biology
Timmermans, S., Souffriau, J., & Libert, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01545 · Cited by 609
Self-citationFresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
Glucocorticoid therapy and ocular hypertension
Dibas, A., & Yorio, T. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.018 · Cited by 75
Metadata
- Authors
- Sundahl, N., Bridelance, J., Libert, C., De Bosscher, K., & Beck, I. M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 152
- Pages
- 28-41
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W211424878
- Cited by
- 216
- References
- 31
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.